

Asparaginase Market Size 2022-2030- Growing Pharmaceutical Industry And Increasing Focus On Research & Development (R&D)

Growth of pharmaceutical and food industries is one of the major factors driving market revenue growth

NEW YORK , NY, UNITED STATES, May 2, 2022 /EINPresswire.com/ -- The global [asparaginase market](#) size is expected to reach USD 2,619.3 Million in 2030 and register a revenue CAGR of 16.7%, according to latest report by



Reports And Data

Reports and Data. Significant growth of pharmaceutical and food industries is one of the important factors expected to drive asparaginase market revenue growth over the forecast period. In addition, market players are investing in research & development and production of asparaginase to meet regulatory specifications with increasing demand. Some macroeconomic factors expected to have a positive impact on the global asparaginase market include increasing population, rapid urbanization, and growing income in several countries across the world.

L-asparaginase is an essential component of the first-line treatment for acute lymphoblastic leukemia (ALL), a type of aggressive blood cancer that is expected to affect over 6,150 people in the U.S. in 2022. Recently, L-asparaginase has been found to have the potential to prevent metastasis from solid tumors as well. Recent advancements in manufacturing and formulation processes have a significant impact on product quality profile, such as contamination, aggregation, and enzymatic activity. Nanomedicine, including technologies such as encapsulation and immobilization, aims at improving asparaginase pharmacokinetics.

Emerging economies, such as China, India, South Korea, Brazil, and Mexico, can offer significant growth opportunities to major market players, due to low regulatory barriers, improvement in healthcare infrastructure, increasing patient population, and rising healthcare expenditure. Regulatory policies in Asia-Pacific are more adaptive and business-friendly than those in developed countries, and moreover, there is increasing competition in mature markets, which has encouraged key players in the target market to focus on emerging countries.

Get a sample of the report @ <https://www.reportsanddata.com/sample-enquiry-form/4306>

Some Key Highlights from the Report:

Based on source, the *Erwinia chrysanthemi* segment is expected register the fastest revenue growth rate over the forecast period. Asparaginase derived from *Escherichia coli* (*E. coli*) can cause allergic reactions in patients, which in turn, is increasing demand for asparaginase obtained from *Erwinia chrysanthemi*. Asparaginase *erwinia chrysanthemi* was first approved by the Food and Drug Administration (FDA) in November 2011, to treat patients with acute lymphoblastic leukemia who are allergic to *E. coli*-derived asparaginase, and it has been used as part of multi-agent chemotherapy. Furthermore, in June 2021, the recombinant form of asparaginase *erwinia chrysanthemi* was approved by the FDA as a component of a chemotherapy regimen, to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the *E. coli*-derived asparaginase.

Based on route of administration, the intramuscularly segment is expected to register a significantly faster growth rate over the forecast period. The intramuscular route of administration is a technique to deliver medications deep into the muscles. Muscles are rich in blood vessels, and hence, absorption of drugs is faster in intramuscular administration. Moreover, intramuscular injections are less invasive, can be done in less time, and have a large injection site (a muscle) compared to intravenous injections.

Based on age group, the adult segment is expected to register a slower revenue growth rate as compared to the pediatric segment, as acute lymphoblastic leukemia is less common in adults. According to the American Cancer Society, about 4 out of every 10 cases of ALL are in adults. Thus, the adult segment is expected to register a slower growth rate over the forecast period.

Based on distribution channel, the hospital pharmacy segment is expected account for largest revenue share during the forecast period. Increasing prescription of medications at hospitals due to more frequent diagnoses at these institutes is driving revenue growth of this segment.

Asia-Pacific market is expected to register a robust revenue CAGR throughout the forecast period. In developing countries, such as India, China, Malaysia, and Indonesia, there is increasing prevalence of acute lymphoblastic leukemia and lymphoblastic lymphoma, which is expected to drive revenue growth of this market. Furthermore, increasing research & development activities in the region are expected to boost market revenue growth over the forecast period. In March 2021, the Indian Institute of Technology, (IIT) Indore, India developed a new asparaginase drug by using the protein engineering approach, to treat acute lymphoblastic leukemia with fewer side effects.

Some major companies profiled in the market report are Jazz Pharmaceuticals (Ireland), Medac GmbH (Germany), Taj Pharmaceuticals Ltd. (India), LGM Pharma (U.S.), Actiza Pharmaceutical Pvt. Ltd. (India), Gennova Biopharmaceuticals (Emcure Pharma) (India), Kyowa Hakko Kirin Co., Ltd. (Japan), Merck (Germany), Servier Pharmaceuticals LLC (France), and Novus Biologicals LLC

(U.S.).

To know more about the report @ <https://www.reportsanddata.com/report-detail/asparaginase-market>

The report also offers detailed insights about market segmentation based on type, application and regional bifurcation:

Asparaginase Market Segmentation:

Source Outlook (Revenue, USD Million, 2019 - 2030)

Erwinia Chrysanthemi
Escherichia Coli

Application Outlook (Revenue, USD Million, 2019 - 2030)

Acute Lymphoblastic Leukemia (ALL)
Lymphoblastic Lymphoma (LBL)

Route of Administration Outlook (Revenue, USD Million, 2019 - 2030)

Intramuscularly
Intravenously

Age Group Outlook (Revenue, USD Million, 2019 - 2030)

Pediatric
Adult

Distribution Channel Outlook (Revenue, USD Million, 2019 - 2030)

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Download Summary @ <https://www.reportsanddata.com/download-summary-form/4306>

Regional Outlook:

North America
U.S.
Canada

Mexico
Europe
Germany
U.K.
Italy
France
BENELUX
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Rest of APAC
Latin America
Brazil
Rest of LATAM
Middle East & Africa
Saudi Arabia
U.A.E.
South Africa
Rest of MEA

Request a customization of the report @ <https://www.reportsanddata.com/request-customization-form/4306>

Thank you for reading the report. Kindly note that we also offer customized reports according to the client requirement. Contact us to know more about the customization feature and our team will provide you with the best customized report.

Read More Reports:

Microbial and Bacterial Cellulose Production Market @ <https://www.reportsanddata.com/report-detail/microbial-and-bacterial-cellulose-production-market>

Thyroid Function Tests Market @ <https://www.reportsanddata.com/report-detail/thyroid-function-tests-market>

Medical Holographic Imaging Market @ <https://www.reportsanddata.com/report-detail/medical-holographic-imaging-market>

Cellular Health Screening Market @ <https://www.reportsanddata.com/report-detail/cellular-health-screening-market>

Vaccines Market @ <https://www.reportsanddata.com/report-detail/vaccines-market>

Clinical Laboratory Tests Market @ <https://www.reportsanddata.com/report-detail/clinical-laboratory-tests-market>

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Tushar Rajput
Reports and Data
+1 212-710-1370

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/570745192>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.